Анализ распространенности и заболеваемости надпочечниковой недостаточностью в мире

1. Kong M.F., Jeffcoate W. Eighty-six cases of Addison’s disease. Clin. Endocrinol. (Oxf.), 1994; 41 (6): 757–761. doi: 10.1111/j.1365-2265.1994.tb02790.x

2. Willis A.C., Vince F.P. The prevalence of Addison’s disease in Coventry, UK. Postgrad. Med. J., 1997; 73 (859): 286–288. doi: 10.1136/pgmj.73.859.286

3. Laureti S., Vecchi L., Santeusanio F., Falorni A. Is the prevalence of Addison’s disease underestimated? J. Clin. Endocrinol. Metab., 1999; 84 (5): 1762. doi: 10.1210/jcem.84.5.5677-7

4. Løvås K., Husebye E.S. High prevalence and increasing incidence of Addison’s disease in western Norway. Clin. Endocrinol. (Oxf.), 2002; 56 (6): 787–791. doi: 10.1046/j.1365-2265.2002.t01-1-01552.x

5. Erichsen M.M., Lovas K., Skinningsrud B., Wolff A.B., Undlien D.E., Svartberg J., Fougner K.J., Berg T.J., Bollerslev J., Mella B., Carlson J.A., Erlich H., Husebye E.S. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J. Clin. Endocrinol. Metab., 2009; 94 (12): 4882–4890. doi: 10.1210/jc.2009-1368

6. Björnsdottir S., Sundström A., Ludvigsson J.F., Blomqvist P., Kampe O., Bensing S. Drug prescription patterns in patients with Addison’s disease: a Swedish population-based cohort study. J. Clin. Endocrinol. Metab., 2013; 98 (5): 2009–2018. doi: 10.1210/jc.2012-3561

7. Meyer G., Neumann K., Badenhoop K., Linder R. Increasing prevalence of Addison’s disease in German females: health insurance data 2008–2012. Eur. J. Endocrinol., 2014; 170 (3): 367–373. doi: 10.1530/EJE-13-0756

8. Regal M., Paramo C., Sierra S.M., Garcia-Mayor R.V. Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clin. Endocrinol. (Oxf.), 2001; 55 (6): 735–740. doi: 10.1046/j.1365-2265.2001.01406.x

9. Tomlinson J.W., Holden N., Hills R.K., Wheatley K., Clayton R.N., Bates A.S., Sheppard M.C., Stewart P.M. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet, 2001; 357 (9254): 425–431. doi: 10.1016/s0140-6736(00)04006-x

10. Shetty V.B., Bower C., Jones T.W., Lewis B.D., Davis E.A. Ethnic and gender differences in rates of congenital adrenal hyperplasia in Western Australia over a 21 year period. J. Paediatr. Child. Health, 2012; 48 (11): 1029–1032. doi: 10.1111/j.1440-1754.2012.02584.x

11. Gleeson H.K., Wiley V., Wilcken B., Elliott E., Cowell C., Thonsett M., Byrne G., Ambler G. Twoyear pilot study of newborn screening for congenital adrenal hyperplasia in New South Wales compared with nationwide case surveillance in Australia. J. Paediatr. Child. Health, 2008; 44 (10): 554–559. doi: 10.1111/j.1440-1754.2008.01383.x

12. Nascimento M.L., Cristiano A.N.B., Campos T. de, Ohira M., Cechinel E., Simoni G., van de Sande Lee J., Linhares R.M.M., da Silva P.C.A. Avaliação de dez anos de um programa de triagem neonatal para hiperplasia adrenal congênita. Arquivos Brasileiros de Endocrinologia e Metabologia, 2014; 58 (7): 765–771. doi: 10.1590/0004-2730000003310

13. Pezzuti I.L., Barra C.B., Mantovani R.M., Januario J.N., Silva I.N. A three-year follow-up of congenital adrenal hyperplasia newborn screening. J. Pediatr. (Rio J.), 2014; 90 (3): 300–307. doi: 10.1016/j.jped.2013.09.007

14. Kopacek C., de Castro S.M., Prado M.J., da Silva C.M., Beltrao L.A., Spritzer P.M. Neonatal screening for congenital adrenal hyperplasia in Southern Brazil: a population based study with 108,409 infants. 428 BMC Pediatr., 2017; 17 (1): 22. doi: 10.1186/s12887-016-0772-x

15. Zhong K., Wang W., He F., Wang Z. The status of neonatal screening in China, 2013. J. Med. Screen, 2016; 23 (2): 59–61. doi: 10.1177/0969141315597715

16. Schweizer R., Blumenstock G., Mangelsdorf K., Ehehalt S., Rossner L., Dorn T., Binder G., Ranke M.B. Prevalence and incidence of endocrine disorders in children: results of a survey in Baden-Wuerttemberg and Bavaria (EndoPrIn BB) 2000–2001. Klin. Padiatr., 2010; 222 (2): 67–72. doi: 10.1055/s-00291241868

17. Kim J.H., Choi S., Lee Y.A., Lee J., Kim S.G. Epidemiology and long-term adverse outcomes in korean patients with congenital adrenal hyperplasia: a nationwide study. Endocrinol. Metab. (Seoul), 2022; 37 (1): 138–147. doi: 10.3803/EnM.2021.1328

18. Zetterström R.H., Karlsson L., Falhammar H., Lajic S., Nordenström A. Update on the Swedish Newborn Screening for Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. Int. J. Neonatal Screening, 2020; 6 (3): 71. doi: 10.3390/ijns6030071

19. Silveira E.L., Santos E.P., Bachega T.A.S., Nader I.L., Gross J.L., Elnecave R.H. The actual incidence of congenital adrenal hyperplasia in brazil may not be as high as inferred – an estimate based on a public neonatal screening program in the state of Goiás. J. Pediat. Endocrinol. and Metab., 2008; 21 (5). doi: 10.1515/jpem.2008.21.5.455

20. Dumic K., Krnic N., Skrabic V., Stipancic G., Cvijovic K., Kusec V., Stingl K. Classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency in Croatia between 1995 and 2006. Hormone Research in Paediatrics, 2009; 72 (5): 310–314. doi: 10.1159/000245933

21. González E.C., Carvajal F., Frómeta A., Arteaga A.L., Castells E.M., Espinosa T., Coto R., Pérez P.L., Tejeda Y., Del Río L., Segura M.T., Almenares P., Robaina R., Fernández J.L. Newborn screening for congenital adrenal hyperplasia in Cuba: Six years of experience. Clin. Chim. Acta, 2013; 421: 73–78. doi: 10.1016/j.cca.2013.02.020

22. Otava F., Novotna D., Kracmar P., Vinohradska H., Stahlova-Hrabincova E., Vrzalova Z., Neumann D., Malikova J., Lebl J., Matern D. Lessons learned from 5 years of newborn screening for congenital adrenal hyperplasia in the Czech Republic: 17-hydroxyprogesterone, genotypes, and screening performance. Eur. J. Pediatr., 2012; 171 (6): 935–940. doi: 10.1007/s00431-011-1656-6

23. Coulm B. Efficiency of neonatal screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency in children born in Mainland France between 1996 and 2003. Arch. Pediatr. Adolesc. Med., 2012; 166 (2): 113. doi: 10.1001/archpediatrics.2011.774

24. Odenwald B., Dörr H.G., Bonfig W., Schmidt H., Fingerhut R., Wildner M., Nennstiel-Ratzel U. Classic congenital adrenal hyperplasia due to 21-hydroxylase-deficiency: 13 years of neonatal screening and follow-up in Bavaria. Klinische Pädiatrie, 2015; 227 (05): 278–283. doi: 10.1055/s-0035-1554639

25. Morikawa S., Nakamura A., Fujikura K., Fukushi M., Hotsubo T., Miyata J., Ishizu K., Tajima T. Results from 28 years of newborn screening for congenital adrenal hyperplasia in Sapporo. Clin. Pediatr. Endocrinol., 2014; 23 (2): 35–43. doi: 10.1297/cpe.23.35

26. Tsuji A., Konishi K., Hasegawa S., Anazawa A., Onishi T., Ono M., Morio T., Kitagawa T., Kashimada K. Newborn screening for congenital adrenal hyperplasia in Tokyo, Japan from 1989 to 2013: a retrospective population-based study. BMC Pediatr., 2015; 15: 209–209. doi: 10.1186/s12887-015-0529-y

27. Heather N.L., Seneviratne S.N., Webster D., Derraik J.G.B., Jefferies C., Carll J., Jiang Y., Cutfield W.S., Hofman P.L. Newborn screening for congenital adrenal hyperplasia in New Zealand, 1994–2013. J. Clin. Endocrinol. Metab., 2015; 100 (3): 1002–1008. doi: 10.1210/jc.2014-3168

28. Gidlöf S., Wedell A., Guthenberg C., von Döbeln U., Nordenström A. Nationwide neonatal screening for congenital adrenal hyperplasia in Sweden. JAMA Pediatr., 2014; 168 (6): 567. doi: 10.1001/jamapediatrics.2013.5321

29. Khalid J.M., Oerton J.M., Dezateux C., Hindmarsh P.C., Kelnar C.J., Knowles R.L. Incidence and clinical features of congenital adrenal hyperplasia in Great Britain. Archives of Disease in Childhood, 2012; 97 (2): 101–106. doi: 10.1136/archdischild-2011-300234

30. Al Hosani H., Salah M., Osman H.M., Farag H.M., El Assiouty L., Saade D., Hertecant J. Expanding the comprehensive national neonatal screening programme in the United Arab Emirates from 1995 to 2011. Eastern Mediterranean Health Journal, 2014; 20 (1): 17–23. doi: 10.26719/2014.20.1.17

31. Larrandaburu M., Matte U., Noble A., Olivera Z., Sanseverino M.T.V., Nacul L., Schuler-Faccini L. Ethics, genetics and public policies in Uruguay: newborn and infant screening as a paradigm. J. Commun. Genet., 2015; 6 (3): 241–249. doi: 10.1007/s12687-015-0236-2

32. Devi A.R.R., Naushad S.M. Newborn screening in India. Ind. J. Pediatr., 2004; 71 (2): 157–160. doi: 10.1007/bf02723099

33. Kaur G., Srivastav J., Jain S., Chawla D., Chavan B.S., Atwal R., Randhawa G., Kaur A., Prasad R. Preliminary Report on Neonatal Screening for Congenital Hypothyroidism, Congenital Adrenal Hyperplasia and Glucose-6-Phosphate Dehydrogenase Deficiency: A Chandigarh Experience. Ind. J. Pediatr., 2010; 77 (9): 969–973. doi: 10.1007/s12098-010-0150-x

34. Steigert M., Schoenle E.J., Biason-Lauber A., Torresani T. High reliability of neonatal screening for congenital adrenal hyperplasia in Switzerland. J. Clin. Endocrinol. Metab., 2002; 87 (9): 4106–4110. doi: 10.1210/jc.2002-012093

35. Larsson A., Thilén A., Hagenfeldt L., von Döbeln U., Guthenberg C. Screening of half a million Swedish newborn infants for congenital adrenal hyperplasia. Screening, 1992; 1 (3): 159–166. doi: 10.1016/09256164(92)90011-s

36. Balsamo A., Cacciari E., Piazzi S., Cassio A., Bozza D., Pirazzoli P., Zappulla F. Congenital adrenal hyperplasia: neonatal mass screening compared with clinical diagnosis only in the Emilia-Romagna region of Italy, 1980–1995. Pediatrics, 1996; 98 (3 Pt 1): 362–367.

37. Cartigny-Maciejewski M., Guilley N., Vanderbecken S., Gondé S., Stuckens C., Ponté C., Weill J., Farriaux J.P. Neonatal screening of congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Lille experience 1980–1996. Archives de Pédiatrie, 1999; 6 (2): 151–158. doi: 10.1016/s0929-693x(99)80202-4

38. Lanting C.I., Verkerk P.H. Evaluatie van de screening op AGS/CHT/PKU bij kinderen geboren in 2002. Leiden: TNO Prevention and Health.

39. Stikkelbroeck M.M.L., van der Kamp H.J., Projectgroep AGS-screening. Neonatale screening op het adrenogenitaal syndroom (AGS), 1998–2001. RIVP rapport 199003063/2002. https://www.rivm.nl/publicaties/neonatale-screening-op-adrenogenitaal-syndroom-ags-1998-2001#abstract_en